Success Metrics

Active Trials
1(13%)

Phase Distribution

Ph phase_3
3
38%
Ph phase_1
1
13%
Ph phase_2
4
50%

Phase Distribution

1

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Other(7)

Detailed Status

unknown7
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 24 (50.0%)
Phase 33 (37.5%)

Trials by Status

unknown788%
active_not_recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_3

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

NCT05732805
unknownphase_2

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

NCT03913923
unknownphase_2

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)

NCT03288870
unknownphase_3

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

NCT03912415
unknownphase_2

International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma

NCT03269565
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05732805Phase 3

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active Not Recruiting
NCT03913923Phase 2

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Unknown
NCT03288870Phase 2

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)

Unknown
NCT03912415Phase 3

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

Unknown
NCT03269565Phase 2

International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma

Unknown
NCT03912389Phase 3

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

Unknown
NCT03912402Phase 2

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Unknown
NCT03050047Phase 1

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors

Unknown

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8